What is a stock summary page? Click here for an overview.
Business Description
Oncotelic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US57667K1097
Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.46 | |||||
| Debt-to-EBITDA | -3.19 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.6 | |||||
| 3-Year EPS without NRI Growth Rate | 69.5 | |||||
| 3-Year FCF Growth Rate | 54.6 | |||||
| 3-Year Book Growth Rate | -38.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.29 | |||||
| 9-Day RSI | 80.56 | |||||
| 14-Day RSI | 77.75 | |||||
| 3-1 Month Momentum % | 12.86 | |||||
| 6-1 Month Momentum % | 88.45 | |||||
| 12-1 Month Momentum % | 9.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.01 | |||||
| Quick Ratio | 0.01 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.9 | |||||
| Shareholder Yield % | -2.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1441.43 | |||||
| ROE % | -40.5 | |||||
| ROA % | -15.87 | |||||
| ROIC % | -1.07 | |||||
| 3-Year ROIIC % | 56.77 | |||||
| ROCE % | -31.6 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.83 | |||||
| Price-to-Tangible-Book | 5.66 | |||||
| EV-to-EBIT | -9.96 | |||||
| EV-to-EBITDA | -9.96 | |||||
| EV-to-Revenue | 576.74 | |||||
| EV-to-Forward-Revenue | 34.57 | |||||
| EV-to-FCF | -40.01 | |||||
| Earnings Yield (Greenblatt) % | -10.04 | |||||
| FCF Yield % | -4.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:OTLC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncotelic Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.07 | ||
| EPS (TTM) ($) | -0.012 | ||
| Beta | -0.27 | ||
| 3-Year Sharpe Ratio | -0.65 | ||
| 3-Year Sortino Ratio | -0.88 | ||
| Volatility % | 103.71 | ||
| 14-Day RSI | 77.75 | ||
| 14-Day ATR ($) | 0.006157 | ||
| 20-Day SMA ($) | 0.052463 | ||
| 12-1 Month Momentum % | 9.78 | ||
| 52-Week Range ($) | 0.017 - 0.07 | ||
| Shares Outstanding (Mil) | 407.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncotelic Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncotelic Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncotelic Therapeutics Inc Frequently Asked Questions
What is Oncotelic Therapeutics Inc(OTLC)'s stock price today?
The current price of OTLC is $0.06. The 52 week high of OTLC is $0.07 and 52 week low is $0.02.
When is next earnings date of Oncotelic Therapeutics Inc(OTLC)?
The next earnings date of Oncotelic Therapeutics Inc(OTLC) is 2025-04-11 Est..
Does Oncotelic Therapeutics Inc(OTLC) pay dividends? If so, how much?
Oncotelic Therapeutics Inc(OTLC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers